Mark G Ward (M G Ward, Xavier Roblin)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 20

Top Topics

Patients With Inflammatory Bowel Disease

Top Venues

Alimentary pharmacology & therapeutics

The Medical journal of Australia

Therapeutic advances in gastroenterology

Journal of gastroenterology and hepatology

This page only lists publications with an associated author ORCID identifier.

Publications

Kathryn Demase, Mark G Ward
Mimics of inflammatory bowel disease: commonly encountered differentials of an uncommon condition. The Medical journal of Australia (2024)
Kathryn Demase, Mark G Ward
Mimics of inflammatory bowel disease: commonly encountered differentials of an uncommon condition. The Medical journal of Australia 221 (3) (2024)
Kathryn Demase, Mark G Ward
Mimics of inflammatory bowel disease: commonly encountered differentials of an uncommon condition. The Medical journal of Australia 221 (3) (2024)
Stéphane Nancey, Mathurin Fumery, Mathias Faure, Gilles Boschetti, Claire Gay, Laurent Milot, Mark G Ward
Use of imaging modalities for decision-making in inflammatory bowel disease. Therapeutic advances in gastroenterology 16 (2023)
Stéphane Nancey, Mathurin Fumery, Mathias Faure, Gilles Boschetti, Claire Gay, Laurent Milot, Mark G Ward
Use of imaging modalities for decision-making in inflammatory bowel disease. Therapeutic advances in gastroenterology 16 (2023)
Robert D Little, Mark G Ward, Emily Wright, Asha J Jois, Alex Boussioutas, Georgina L Hold, Peter R Gibson, Miles P Sparrow
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics. Journal of clinical medicine 11 (20) (2022)
Alexander Keith Bain Turbayne, Mark G Ward
Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Alimentary pharmacology & therapeutics 53 (12) (2021)
Ralley E Prentice, Clarissa Rentsch, Aysha H Al-Ani, Eva Zhang, Douglas Johnson, John Halliday, Robert V Bryant, Jacob Begun, Mark G Ward, Peter J Lewindon, Susan J Connor, Simon Ghaly, Britt Christensen
SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 3 (4) (2021)
David J Gibson, Mark G Ward, Clarissa Rentsch, Antony B Friedman, Kirstin M Taylor, Miles Patrick Sparrow, Peter R Gibson
Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 51 (6) (2020)
Emma K Flanagan, Peter R Gibson, Emily K Wright, Gregory T Moore, Miles Patrick Sparrow, William Connell, Michael A Kamm, Jakob Begun, Britt Christensen, Peter De Cruz, Edward Shelton, Damian Dowling, Jane M Andrews, Steven J Brown, Olga D Niewiadomski, Mark G Ward, Ourania Rosella, Gennaro Rosella, Katerina V Kiburg, Alyson L Ross, Sally J Bell, null null
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary pharmacology & therapeutics 52 (10) (2020)
Jonathan Digby-Bell, Mark G Ward
Editorial: balancing safety and efficacy-6-TGN thresholds in NUDT15 intermediate metabolisers treated with thiopurines. Alimentary pharmacology & therapeutics 52 (3) (2020)
Ashish Srinivasan, Daniel R Van Langenberg, Robert D Little, Miles P Sparrow, Peter De Cruz, Mark G Ward
A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. Alimentary pharmacology & therapeutics 51 (12) (2020)
David J Gibson, Mark G Ward
Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed. Alimentary pharmacology & therapeutics 49 (6) (2019)
C Rentsch, B Headon, Mark G Ward, P R Gibson
Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response? Journal of gastroenterology and hepatology 33 (1) (2019)
Mark G Ward, Miles P Sparrow, Mark G Ward
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therapeutic advances in gastroenterology 11 (2018)
Mark G Ward, P M Irving
Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply. Alimentary pharmacology & therapeutics 46 (4) (2017)
Mark G Ward, P R Gibson, Miles Patrick Sparrow
Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply. Alimentary pharmacology & therapeutics 45 (11) (2017)
Nikola Mitrev, N Vande Casteele, Cynthia H-T Seow, J M Andrews, S J Connor, G T Moore, M Barclay, J Begun, R Bryant, Webber Pak Wo Chan, C Corte, S Ghaly, D A Lemberg, V Kariyawasam, P Lewindon, J Martin, R Mountifield, G Radford-Smith, P Slobodian, Miles Patrick Sparrow, C Toong, D van Langenberg, Mark G Ward, Rupert W L Leong, null null
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary pharmacology & therapeutics 46 (11-12) (2017)
Mark G Ward, B Warner, N Unsworth, S-W Chuah, C Brownclarke, S Shieh, M Parkes, J D Sanderson, Z Arkir, J Reynolds, P R Gibson, P M Irving
Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Alimentary pharmacology & therapeutics 46 (2) (2017)
Mark G Ward, P A Thwaites, L Beswick, J Hogg, G Rosella, D Van Langenberg, J Reynolds, P R Gibson, M P Sparrow
Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Alimentary pharmacology & therapeutics 45 (8) (2017)